Evaluation of usage of bone scan index in assessment of metastatic prostate cancer

Halil Ćorović,Safet Hadžimusić,Nusret Salkica,Adel Brčaninović,Enis Tinjak

doi:10.48026/issn.26373297.2021.12.1.1

Halil Ćorović, Safet Hadžimusić + Show 3 more

Open Access

https://doi.org/10.48026/issn.26373297.2021.12.1.1

Copy DOI

Abstract

Introduction: Prostate cancer has been the leading type of cancer to affect male population, and as such, it is a subject to efforts to furthermore diagnostic tools already in existence as well as development of new ones which will Aid early diagnostic, treatments as well as a follow up procedures and clinical trials. Bone scan index is a useful and objective biomarker used as a valuable tool for determination as to precise bone involvement in advanced cases, as well as a tool to predict the outcome in prostate cancer patients in clinical trials.Methods: This paper is a non-experimental (qualitative) research, that is, a scientific review of the literature.Results: The results we analyzed in this paper were collected from published academic journals.Conclusion: As a new imaging biomarker, bone scan index has potential to predict therapeutic effects and survival of patients with prostate cancer. Using measurable diagnostic image parameters, the bone scan index is important for determining metastatic bone changes in prostate cancer patients.

Highlights

Prostate cancer has been the leading type of cancer to affect male population, and as such, it is a subject to efforts to diagnostic tools already in existence as well as development of new ones which will Aid early diagnostic, treatments as well as a follow up procedures and clinical trials
Bone scan index is a useful and objective biomarker used as a valuable tool for determination as to precise bone involvement in advanced cases, as well as a tool to predict the outcome in prostate cancer patients in clinical trials
Scan Index (BSI)’’ which provides a quantitative prostate cancer with bone specific antigen (PSA) is the best marker for Prostate cancer (PCa) monitoring, measure of the percentage of the adult skeleton it is not PSA that represents or reflects the involved by bone metastases

Summary

Introduction

1.4 million people are diagnosed with cancer every year in the USA. Of these, half of patients suffer from a cancer that frequently metastasizes to bones [1]. Several studies have attempted to correlate the extent of skeletal metastatic involvement with survival in patients with advanced prostate cancer. Scan Index (BSI)’’ which provides a quantitative PSA is the best marker for PCa monitoring, measure of the percentage of the adult skeleton it is not PSA that represents or reflects the involved by bone metastases. It has been comprehensive status of PCa aggressiveness. BSI measures the tumor burden in bones as a percentage of the total skeletal mass and has been shown to be associated with survival of patients with prostate cancer [31]. The aim of this study is to provide assessment as to involvement of bone scan index to diagnostic procedures and the gradation to which bone scan index is relevant for determination of the metastatic changes on bones in patients with advanced prostate cancer

Materials and methods

Aim

Discussion

Conclusions